For AbbVie, boring is good. The company's first quarterly earnings report since its split from Abbott met or slightly beat consensus expectations as Humira continued to drive revenue growth with a 16% year-over-year sales bump.
For AbbVie, boring is good. The company's first quarterly earnings report since its split from Abbott met or slightly beat consensus expectations as Humira continued to drive revenue growth with a 16% year-over-year sales bump.
AbbVie had $4.3 billion in revenue for the first quarter of 2013, which was up 3.7% from the same period...
Create an account to read this article
Already a subscriber?
The Danish firm's atopic dermatitis drug Adbry is performing well despite strong competition from Sanofi/Regeneron’s Dupixent.
The Belgian company has raised its outlook for full-year sales following a strong launch for Bimzelx in hidradenitis suppurativa in the first half of 2025.
The Phase IIb study failed its primary and a key secondary endpoint, but showed activity on another key secondary and an exploratory endpoint.
The Danish medical dermatology specialist boosts its sales force ahead of the launch of Anzupgo.
There is little to divide the Phase III results for the two aldosterone synthase inhibitors, though AstraZeneca’s combination and cardiovascular outcomes studies could bear fruit in the long-term.
The biotech announced positive topline Phase I/II results for the BCL2 inhibitor in late-line mantle cell lymphoma, with Phase III studies underway in chronic lymphocytic leukemia.
Johnson & Johnson will push ahead with its 'pipeline-in-a-product' plans for Imaavy despite pulling the plug on its development in rheumatoid arthritis.
